[inaudible] [inaudible] [inaudible] the russian they believed that they should say no Russian Troops in ukraine. In here the Current Situation ukraine was so efficient because there so many propaganda by the west. The propaganda was with the language of world war ii the main symbol of the victory of the world war ii in 1945. And the third very important look what happened in ukraine. Through the war in the battle the population has very horrific memories. This is a very significant reason. Of course russia violates what International Law but the key punishment and therefore an ethical. Therefore it is unethical act because russia restores its status by conducting ethical policy. Its not only people but also service of a system of protection of defense. Therefore despite the fact that one other way official media say theyre only volunteers there, people are perfectly aware that Russian Military the volunteers were the troops fight their and this is the right thing because there were is the worst cheating in the war. Trimmer questions but they must be very short. Will very quickly respond to these because we are already past time. I see three handset. I like to ask in the context of the if youre defined as a foreign agent. With american propaganda being such a cornerstone of pollutants popularity, his notion that president putin, im sorry President Trump can make a deal to reset relations with russia fanciful. The last question in the back. So these are two questions of the were done. Will result or what outcome is more positive for russia. 52 30 said trump would be better for russian only 9 spoke about clinton. Therefore the trump and prudent should be the successor putin. [inaudible] [inaudible] we have lost a court case. [inaudible] clearly and politically they ordered not going up against the Civil Defense and general asking against the National Memorial another of these 48 were included. I think it was highly to play a role. But this also came a number because we did not yet receive any, we earn this money for research and our partner, the commercial company they did not do anything to do with the organization of which they will go by. The second would be the pressure in the region and environmental official throughout with our employees which blocks the opportunity to come back and conducted number of projects which we had with russian. [inaudible] another relation with the worker, another words to ask the local administration. Its not only financial and finally, we are not going to apply to the registered and that means we are going to be honest again and to grow twice or three times and then it will be banned officially. So our forecasts is very bad. I believe we still have half a year. So all of the putin. [inaudible] it was a fascinating conversation about whats going inside russia. [applause] i also want to thank our cosponsors, the institute for your pain russia and eurasias studies, cspan and tall of you for coming. I wish you i wish you a happy thanksgiving. Thank you much. [applause] [inaudible] [inaudible] up next up next on cspan two, panel discussing how the Trump Administration might approach the issues of biomedical innovation, healthcare, and drug pricing. That a pricing. That a look at how Food Companies market to children. Later, in case case you just misted a conversation on russia under vladimir putin. Cspans washington journal, live every day with new some policy issues that impact you. Coming up thursday morning, economic adviser to president elect trump Stephen Moore joins us to discuss mr. Trumps a proposal to lower taxes and increase the number of jobs and plans to grow the economy then robert weissman, president of the Nonprofit OrganizationPublic Citizen will talk about their plans to fight the Trump Administration on deregulation. Watch cspans washington journal live 7 00 a. M. Eastern on thursday morning. Join the discussion. Next a conversation on biomedical innovation, healthcare and drug pricing. Panelists include a health a Health Policy advisor to president obamas Transition Team, former fda commissioner in a Pharmaceutical Company vice president. The Milken Institute hosted the event in new york city. Thank you for being here. Regardless of your politics ii think it is safe to say this past week has been a little tumultuous. For policy. I think think either way, no matter who won theand c. Election healthcare issues would have been front and center. You can imagine that were Hillary Clinton is president elect of having a panel on the drug pricing crackdown. Instead because donald trump is our president elect the new hasd been dominated with talk of obama care repeal. Some of the issues most important to the sector have been a little over shadow. Foris me me selfishly this is a treat, ive had my head down and with what the epas first steps is gonna look like. Im curious to know what happene for the sector by bright experts to talk to that this morning. I think we will start is this, sitting in this room we are 1 mile exactly from trump tower. If i l i looked on google maps, maybe maybe apple maps has a slightly different calculation. Tom trump tower has 58 floors. For the sake of argument will say it takes about a second or so to go up every floor. Imagine you. Imagine you are riding the elevator with the president elect and hypothetically he might not know a lot about the inner workings ofow healthcare, just go with me on this. Imagine you can tell him anything about this industry, what is what is your literal elevator pitch in 60 seconds. I am going to tell mr. Trump to think very carefully about policies that have an impact on the pharmaceutical industry. Like ge, that bring good thing to light, we are in good things to life and to people. Innovation is is crucially important to keeping our country healthy as well is to keeping our country prosperous. Our companies employ tens ofco thousands of people in good paying, scientific and technological jobs so we do contribute to the economy, most and partly our number one priority and the thing that we make our greatest contribution to his patients all over this country and globally whose lived we saves and in whose lives we make a huge and important difference. His policies could change that dynamic not only for companiesde individuallys buffer every single patient in america. Do i have another few seconds . I think he says there six or eight floors but depending on how you take it. How about you . I would tell mr. President elect , i know you have recommendation for names and appointments, but i would employ you to put policy before people and persons. What i mean by that is whoever you select ultimately is going to have to do with the fact that there are enormous policy issues and changes that are going to affect the federal agencies that are involved in healthcare and Biomedical Research. We are looking at for example former commissioners of the f da has been working on the recommendation of the food and Drug Administration and all the new onset goes with that. There are now over ten federal agencies that fund Biomedical Research to the extent of tens of billions of dollars. There is a significant policy question around do we need to have a greater coordination of that federal spending as a boost to a policy that in braces Public Private partnerships in the relationship with industry. So so before making critically important decisions about personnel, i believe its important for you and youran leadership to pay very close attention to the macro policy questions that are going to shape the future of Biomedical Research, and therefore the future of healthcare in this country. So i would certainly say ditto to both of those very eloquent elevator speeches, myself very much hammer home to folks on patient send us much porridge progress as we have made a point out that there are thousands of Rare Diseases for which there are no treatmentshe and families that are suffering. I would hammer home on the economic message. I. I think that would resonate with his campaign. In terms of the number of jobs and what it means and otherreseh research centers, but its a little bit different just to think the other message that i think we should talk about is the need for Global Partnerships and some of his comments in the context of trade have suggested that we might not have the same level of collaboration globally and i would want to point out this is not an industry that can go forward alone, is very much dependent on collaborationndentl agreements and harmonization is another big thing to focus on. That would be a third message tn focus on and finally i wouldo want to emphasize that we need to be mindful of impact across all Patient Population groups being mindful of health equityml considerations and particularly giving some of the rhetoric of the campaign that this is an area that we would have to be sensitive to in the days ahead. His head is swirling withswid important things. I think i would probably start off on the six floor after the massive escalator strut me up. I would just say echoing all the things that have been said, and a a new leader in the position has a kneejerk reaction to want to take action quickly. I think if he has done his 90 day plan one of the most important things he could do is take a step back and really listen. He has shown an uncanny ability to listen to voices that have previously been on heard around the country. In some ways thats what we need to do for any major policy change is take a step back and understand what the system does look like, the complexity of it and the fact that Companies Like myself operate in 150 countries all over the world, and really understand the problems that are facing them. The problems facing this country in our industry were the samee before and after the election. What the first thing he could do is really set a tone for the principle and how he wants to resolve those issues. So of principle a Patient First and really wanted to stimulate an economy to provide an environment that rewards and supports innovation but also one that meets and addresses the needs of a lot of voices out there that are looking for the continued options for affordable healthcare. He also can set a tone by reaching out to the business sector and to all of us in the room and say the way of getting there is not just go with small pleat bowl in the room but to reach out and listen to the ideas that each one of you and each one of us in the sector may have to address the problems. Before i start i should tello you that margaret gave me the slides last night. And so i dont quite get. Im happy to have that conversation. This is what the people came to hear. [laughter] the elevator hasnt started yet. I think we have a president who probably doesnt understand the nuances of healthcare and Biomedical Research. Sa so i would say to him and give him a little history and remind him in 1945 bush road at the request of roosevelt a report about how the federal government could relate to science having just come out of the war effort in having the developed an important relationship with thet community what is going to come next, should we just stop now that we dont have a warning warning more in the answer surprised roosevelt and manyot others and what he said was support basic research. The federal government must support basic research becausese private sector cannot. It operates on a different timescale, and ask ask openended questions i cannot be answered. Th so the first answer is that and that is, enunciate, use your pulpit, enunciate the importance of fundamental discovery. We heard julie answer a stirring call to remind us of the importance of that. Ec the second message would be the the federal is expanded because of the way that Scientific Research has gone in the connection to patients andnd Health Healthcare that is that we nownu need to build a continuum from that fundamental discovery all the way beyond clinician and social behavioral and population scientists into the community ob patients but also that of Healthy People because its by gathering and operating together that we will be able to gather the information needed in this new world of big data that will be able to establish connections that will allow us to see through to mechanisms of disease in a process to curing them. Wah ive heard somethings overlap and maybe we should jusu have a base now that weve informed the next president on where we stand, republicans will hold onto congress, they will now control the white house. Was this election ultimately good for this sector . And as someone who is seen the industry from different angles lets start from you was thent selection good for the sector . I believe it it has the potential to be incredibly positive. I would justify that in a few different ways first of all, i think with the new this new administration and with a view towards tax policy and regulatory policy i believe theres the opportunity for an enriched climate for this sector. On one hand addressing issues about repatriation, trillions of dollars available to be brought back into this country. Hundreds of billions of dollars on the Balance Sheets of major corporations in this country goo like google and that money has basically been sitting on the sideline. Right fiscal pol with the right tax policies in the right Investment Policies we have the opportunity to pull that back and an opportunity for enriched investment. We can talk about infrastructure but infrastructure for the biomedical community including infrastructure around data and education of the next generation those can be themed that this fm administration couldnt erase. Then you have the other regulatory issues about reforms in the regulatory process at thi fda which could create a much more exciting climate for earlystage investment or Venture Capitalists because thee pipeline could not get a bit more precise and more optimistic. Ve i believe from those standpoints when you couple that with the continued explosion that will occur as keith pointed out in science and technology itself, the next four years could be the best of times not the worst of times. And i overall some optimism for the sector, repatriation and so on, do you agree with andys assessment . I agree with it and i think the Financial Markets agreedee with that as well. The market went up right after the election. Within hours of the election, first dropped and then went back up the number of analysts in particular pointed out this is the time to invest in the biopharmaceutical industry. I think they made that recommendation based on what andy was talking of but also another issue and that is the issue of the assault on drug pricing that has been taking place and was one of the cornerstones of secretary clintons campaign. That assault on drug pricing could have had a continuing downside impact on the industry. I think the expectation now that secretary clinton is not in the white house is that at least to some extent, some of the pressure that places all of this emphasis on the price of drugs instead of talking about the value of drugs is going to settle down a bit. Ty to tell he will give our industry an opportunity to tell her story more directly and without a higa level of acrimonious debate. Our story is about patience andb value. Its about the fact that our Healthcare System is a multi partition operation such as about the price of one product including prescription drugs that they need. I th that conversation of how all the how they can all Work Together that access to drugs and the other services in the system can take place more effectively in a non shrieking environment. I think that is what we can expect to have in thisis particular case. Lets put the patient issue on a spending plan come back to it in a moment. The idea that secretary clinton to your point donald trump has heard he is not a stranger to campaigning on the hydra price issue two. While republicans in congresst might be a bit more tepid thera democrats you dont know really know that donald trump can do. I do think that we have to acknowledge that there are a lot of consumers who when they go to the pharmacy counter face payments and insurance rates that are not affordable fore not them. That didnt change after the election. We have i think for us as a company we look at that and we know we have to take our own actions and own responsibilities. So for us not even in the last two years, the last five years we priced our things responsibility to be at or below the therapies were looking toe replace. Thats a fact that we as an industry have to continue to build upon. Its not just about our science and and innovation is about us working as a responsible company, and industry within the ecosystem acknowledging the role that we play in saving lives and addressing illnesses but also i what we can do to help improve e healthcare and make that system or sustainable. Lets put this route for a second, in the world were secretary clinton had been elected and maybe theres more focus on drug pricing, our solutions better or worse off, let me ask more directly, did donald trump selection, did the results of last tuesday help or hurt americas patients ultimately . I think you have to take a step back and say at this dialogue at this point time i think with the campaign that are bad for sector at some point you have to start at the top and look back at president elect trumps record and in terms of his Campaign Proposal they have been not particularly welltherea detailed, there is not a meaningful focus on biomedical or b